Class II recall: Baxter Healthcare Corporation: Famotidine Injection in Sodium Chloride Injection, 20 mg, 50 mL in GALAXY Single
Baxter Healthcare Corporation has issued a Class II recall for Famotidine Injection in Sodium Chloride Injection (20 mg/50 mL) supplied in GALAXY Single Dose Containers, NDC 0338-5197-41. The recall notice cites current Good Manufacturing Practice (CGMP) deviations as the reason for the action; no further clinical details were provided in the source.
Most relevant for: Hospital and inpatient care settings using intravenous famotidine, including gastroenterology services managing acid-related conditions requiring parenteral H2-receptor antagonist therapy.
Read the original at FDA Drug Enforcement ReportsSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More family medicine updates
- Long-Acting Injectable HIV Therapy Noninferior for Adherence ChallengesOct 15, 2026
- 8-week sofosbuvir-velpatasvir regimen non-inferior to 12 weeks for HCVSep 30, 2026
- Lean MASLD shows milder histology but similar mortality outcomesSep 30, 2026
- Oral GLP-1 orforglipron shows cardiovascular non-inferiority to insulin glargineSep 30, 2026
- Retatrutide produces substantial weight loss in phase 3 diabetes trialSep 29, 2026